Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of triamcinolone acetonide, a corticosteroid, and indomethacin, a non-steroidal anti-inflammatory drug (NSAID). Triamcinolone acetonide is a synthetic glucocorticoid that prevents the release of substances in the body that cause inflammation. Indomethacin is an NSAID with anti-inflammatory, analgesic, and antipyretic properties that works by inhibiting the synthesis of prostaglandins. This combination is particularly used in the treatment of acute gout, with triamcinolone acetonide being as safe and effective as indomethacin alone. The combination is especially useful for patients who have contraindications to therapy with NSAIDs alone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on triamcinolone acetonide + indomethacin.